Impaired anti-tumor activities of the CAR T cells following CRISPR/Cas9-mediated ablation of HER2 in the melanoma cells outlined the specific antitumor effects of HER2-specific CAR T cells against melanoma cells [144]. The gene discussed is ERBB2; the disease is melanoma.